Recent Metabolomics Analysis in Tumor Metabolism Reprogramming

Abstract

Metabolic reprogramming has been suggested as a hallmark of cancer progression. Metabolomic analysis of various metabolic profiles represents a powerful and technically feasible method to monitor dynamic changes in tumor metabolism and response to treatment over the course of the disease. To date, numerous original studies have highlighted the application of metabolomics to various aspects of tumor metabolic reprogramming research. In this review, we summarize how metabolomics techniques can help understand the effects that changes in the metabolic profile of the tumor microenvironment on the three major metabolic pathways of tumors. Various non-invasive biofluids are available that produce accurate and useful clinical information on tumor metabolism to identify early biomarkers of tumor development. Similarly, metabolomics can predict individual metabolic differences in response to tumor drugs, assess drug efficacy, and monitor drug resistance. On this basis, we also discuss the application of stable isotope tracer technology as a method for the study of tumor metabolism, which enables the tracking of metabolite activity in the body and deep metabolic pathways. We summarize the multifaceted application of metabolomics in cancer metabolic reprogramming to reveal its important role in cancer development and treatment.

Regulation of oxidative phosphorylation by Nuclear myosin 1 protects cells from metabolic reprogramming and tumorigenesis in mice

“…Among others, the analysis revealed glycolysis, sugar metabolism, amino acid, and fatty acid metabolism pathways to be enriched in the NM1 KO Cells with increased levels of the majority of identified compounds while the TCA cycle and OXPHOS pathways were suppressed in these cells (Figure 3O). This correlates well with our previous findings and suggests that NM1 KO cells not only switch to aerobic glycolysis but fully reprogram to cancerous metabolism as several recent studies show similar metabolomic profiles in different cancer types (Han et al, 2021). For example, deregulated fatty acid and glucose metabolism were found in lung cancer patients (Callejon-Leblic et al, 2019); nucleotide, histidine, and tryptophan metabolism in ovarian cancer (Zhang et al, 2013); and most prominently, purine metabolism, glycine, serine, arginine and proline metabolism, steroid biosynthesis, sphingolipid metabolism and bile metabolism deregulated in pancreatic cancer (Luo et al, 2020).…”

Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer

“…Monitoring of changes in the levels of various metabolites in cancer cells or body fluids may be a potential source of new cancer biomarkers. To date, many studies have been published indicating the high potential of metabolomic markers in the diagnosis of various cancers and in understanding of the mechanisms of cancer initiation and development 28 .…”

Metabolomics in Radiotherapy: Current Paradigms and Future Perspectives

“…For decades, many studies have been conducted for the early diagnosis and treatment of tumors, using various detection techniques. Metabolomics help in the identification and validation of metabolic biomarkers that have the potential to diagnose tumor field progression and metastasis in the in vitro environment (Han et al, 2021). The potential findings of major metabolome studies in various types of cancers and how it affects various metabolic pathways have been highlighted (Table 1).…”